<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00557882</url>
  </required_header>
  <id_info>
    <org_study_id>2006-336</org_study_id>
    <nct_id>NCT00557882</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Vaginal Mesh for Anterior Prolapse</brief_title>
  <acronym>VAMP-A</acronym>
  <official_title>A Randomized Clinical Trial of Vaginal Mesh for Anterior Prolapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medstar Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medstar Health Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this double-blind, randomized clinical trial (RCT) is to test the&#xD;
      hypothesis that the addition of a standardized technique of interpositional synthetic&#xD;
      polypropylene mesh placement improves the one-year outcome of vaginal reconstructive surgery&#xD;
      for anterior prolapse compared to traditional vaginal reconstructive surgery without mesh.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple vaginal, abdominal and laparoscopic procedures have been described for surgical&#xD;
      correction of pelvic support problems. However, conventional pelvic reconstructive surgeries&#xD;
      have been associated with a 20-30% prolapse recurrence rate. The anterior vaginal wall is the&#xD;
      site most often recognized as the area of vaginal prolapse recurrence. Minimally invasive&#xD;
      surgical procedures using mesh have rapidly developed in the field of pelvic floor&#xD;
      reconstruction in an attempt to improve surgical cure rates. Unfortunately, safety and&#xD;
      efficacy data have lagged behind the technical advancements.&#xD;
&#xD;
      This trial will randomize women with advanced anterior wall prolapse to two treatment arms:&#xD;
      vaginal reconstructive surgery with mesh and vaginal reconstructive surgery without mesh. The&#xD;
      primary outcome is cure of anterior wall prolapse at one year. Secondary outcomes are cure of&#xD;
      apical and posterior wall prolapse, quality-of-life measures and complication rates. Patients&#xD;
      will be approached for recruitment only after they have made the decision to undergo vaginal&#xD;
      surgery for anterior prolapse. The patient and examiner will be blinded to the surgical&#xD;
      treatment assignment. Interim measurement of primary and secondary outcomes will be conducted&#xD;
      three months post-operatively. Additional follow-up will be conducted at one-year intervals&#xD;
      subsequent to the expected one-year endpoint.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Outcome Measure for Objective Treatment Success is Anterior Prolapse, Point Ba at Stage 0 or 1 (Defined as Maximal Descent of the Anterior Wall to Greater Than 1 cm Above the Hymen) at One Year.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Vaginal Prolapse</condition>
  <condition>Uterine Prolapse</condition>
  <condition>Cystocele</condition>
  <condition>Pelvic Organ Prolapse</condition>
  <arm_group>
    <arm_group_label>mesh</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vaginal reconstructive surgery with synthetic polypropylene mesh</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no mesh</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vaginal reconstructive surgery without mesh</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>synthetic polypropylene mesh</intervention_name>
    <description>Mesh used will be synthetic monofilament polypropylene. In this trial, patients in the experimental group will undergo interpositional multi-armed mesh placement using trocars for transobturator +/- ischioanal fossa placement at the level of the ischial spine.</description>
    <arm_group_label>mesh</arm_group_label>
    <arm_group_label>no mesh</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. women age &gt; 21&#xD;
&#xD;
          2. diagnosed with stage II-IV vaginal prolapse who desire reconstructive surgery&#xD;
&#xD;
          3. available for 12 months of follow-up&#xD;
&#xD;
          4. able to complete study questionnaires and assessments.&#xD;
&#xD;
          5. available for 12 months follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Uterus in place.&#xD;
&#xD;
          2. No anterior vaginal prolapse.&#xD;
&#xD;
          3. Medical contraindications, e.g. current urinary tract, vaginal or pelvic infection,&#xD;
             history of pelvic irradiation, history of lower urinary tract malignancy, chronic&#xD;
             steroid use or a compromised immune system.&#xD;
&#xD;
          4. Current intermittent self catheterization.&#xD;
&#xD;
          5. Pregnancy or desire for future fertility.&#xD;
&#xD;
          6. Presence of an adnexal or ovarian mass.&#xD;
&#xD;
          7. Shortened vagina.&#xD;
&#xD;
          8. Other laparoscopic or abdominal/pelvic surgery in the past 3 months.*&#xD;
&#xD;
          9. Known neurologic or medical condition affecting bladder function, e.g. multiple&#xD;
             sclerosis, spinal cord injury.&#xD;
&#xD;
         10. Need for surgery requiring an abdominal incision.&#xD;
&#xD;
         11. &lt;12 months post-partum. (Enrollment can be deferred until time requirement has been&#xD;
             met).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew I Sokol, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medstar Health Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wahington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://medstarresearch.org/</url>
    <description>Click clinical trials for more information about this study &quot; A Randomized Clinical trial of Vaginal Mesh for Prolapse&quot;</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 13, 2007</study_first_submitted>
  <study_first_submitted_qc>November 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2007</study_first_posted>
  <results_first_submitted>September 4, 2020</results_first_submitted>
  <results_first_submitted_qc>October 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 30, 2020</results_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prolapse</keyword>
  <keyword>uterus</keyword>
  <keyword>mesh</keyword>
  <keyword>bladder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystocele</mesh_term>
    <mesh_term>Uterine Prolapse</mesh_term>
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mesh</title>
          <description>Vaginal reconstructive surgery with synthetic polypropylene mesh&#xD;
synthetic polypropylene mesh: Mesh used will be synthetic monofilament polypropylene. In this trial, patients in the experimental group will undergo interpositional multi-armed mesh placement using trocars for transobturator +/- ischioanal fossa placement at the level of the ischial spine.</description>
        </group>
        <group group_id="P2">
          <title>no Mesh</title>
          <description>Vaginal reconstructive surgery without mesh&#xD;
synthetic polypropylene mesh: Mesh used will be synthetic monofilament polypropylene. In this trial, patients in the experimental group will undergo interpositional multi-armed mesh placement using trocars for transobturator +/- ischioanal fossa placement at the level of the ischial spine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mesh</title>
          <description>Vaginal reconstructive surgery with synthetic polypropylene mesh&#xD;
synthetic polypropylene mesh: Mesh used will be synthetic monofilament polypropylene. In this trial, patients in the experimental group will undergo interpositional multi-armed mesh placement using trocars for transobturator +/- ischioanal fossa placement at the level of the ischial spine.</description>
        </group>
        <group group_id="B2">
          <title>no Mesh</title>
          <description>Vaginal reconstructive surgery without mesh&#xD;
synthetic polypropylene mesh: Mesh used will be synthetic monofilament polypropylene. In this trial, patients in the experimental group will undergo interpositional multi-armed mesh placement using trocars for transobturator +/- ischioanal fossa placement at the level of the ischial spine.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.4" spread="10.8"/>
                    <measurement group_id="B2" value="63.5" spread="8.9"/>
                    <measurement group_id="B3" value="63.94" spread="9.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Outcome Measure for Objective Treatment Success is Anterior Prolapse, Point Ba at Stage 0 or 1 (Defined as Maximal Descent of the Anterior Wall to Greater Than 1 cm Above the Hymen) at One Year.</title>
        <time_frame>1 year</time_frame>
        <population>NIH optimal prolapse cure (Pelvic Organ Prolapse Quantifications System (POP-Q) stage &lt;1)</population>
        <group_list>
          <group group_id="O1">
            <title>Mesh</title>
            <description>Vaginal reconstructive surgery with synthetic polypropylene mesh&#xD;
synthetic polypropylene mesh: Mesh used will be synthetic monofilament polypropylene. In this trial, patients in the experimental group will undergo interpositional multi-armed mesh placement using trocars for transobturator +/- ischioanal fossa placement at the level of the ischial spine.</description>
          </group>
          <group group_id="O2">
            <title>no Mesh</title>
            <description>Vaginal reconstructive surgery without mesh&#xD;
synthetic polypropylene mesh: Mesh used will be synthetic monofilament polypropylene. In this trial, patients in the experimental group will undergo interpositional multi-armed mesh placement using trocars for transobturator +/- ischioanal fossa placement at the level of the ischial spine.</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Outcome Measure for Objective Treatment Success is Anterior Prolapse, Point Ba at Stage 0 or 1 (Defined as Maximal Descent of the Anterior Wall to Greater Than 1 cm Above the Hymen) at One Year.</title>
          <population>NIH optimal prolapse cure (Pelvic Organ Prolapse Quantifications System (POP-Q) stage &lt;1)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Mesh</title>
          <description>Vaginal reconstructive surgery with synthetic polypropylene mesh&#xD;
synthetic polypropylene mesh: Mesh used will be synthetic monofilament polypropylene. In this trial, patients in the experimental group will undergo interpositional multi-armed mesh placement using trocars for transobturator +/- ischioanal fossa placement at the level of the ischial spine.</description>
        </group>
        <group group_id="E2">
          <title>no Mesh</title>
          <description>Vaginal reconstructive surgery without mesh&#xD;
synthetic polypropylene mesh: Mesh used will be synthetic monofilament polypropylene. In this trial, patients in the experimental group will undergo interpositional multi-armed mesh placement using trocars for transobturator +/- ischioanal fossa placement at the level of the ischial spine.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>mesh erosion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
              <event>
                <sub_title>Postoperative blood transfusion</sub_title>
                <description>Postoperative blood transfusion for participant with concurrent hystorectomy</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>cystotomy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew Sokol, MD</name_or_title>
      <organization>MedStar Washington Hospital Center</organization>
      <phone>2028776526</phone>
      <email>andrew.i.sokol@medstar.net</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

